Skip to main content
SpringerLink
Log in

Secondary cytoreduction for patients with recurrent ovarian cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Standard treatment for advanced epithelial cancer includes primary cytoreductive surgery followed by combination chemotherapy. Optimal primary debulking is associated with improved clinical response rates to primary chemotherapy and longer overall survival. Still, at least 60% of advancedstage ovarian cancer patients who are without clinical evidence of disease after completing primary therapy ultimately develop recurrent disease. Despite significant efforts, standard treatment of patients with recurrent ovarian cancer remains poorly defined. In view of the new refinement in surgical techniques and medical treatments and the extended disease-free interval, physicians and patients face the dilemma of how to handle further management in this subgroup of patients. A clear understanding of the prognostic factors and expectations from the procedure are necessary in order to identify candidates adequately.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Murray T, Ward E, et al.: Cancer statistics 2005. CA J Clin 2005, 55:10–30.

    Article  Google Scholar 

  2. Ries LAG, Eisner MP, Kosary CL, et al eds.: SEER cancer statistics review, 1975–2001. Bethesda, MD: National Cancer Institute; 2001. |http://seer.cancer.gov/csr/1975_2001/|url

    Google Scholar 

  3. Meigs JV: Tumors of the Female Pelvic Organs. New York: McMillan; 1935.

    Google Scholar 

  4. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Monogr Natl Cancer Inst 1975, 42:101–104.

    CAS  Google Scholar 

  5. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992, 47:159–166.

    Article  PubMed  CAS  Google Scholar 

  6. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974–980.

    PubMed  CAS  Google Scholar 

  7. Boente MP, Chi DS, Hoskins WJ: The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998, 25:326–334.

    PubMed  CAS  Google Scholar 

  8. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977, 61:1307–1317.

    PubMed  CAS  Google Scholar 

  9. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727–1733.

    PubMed  CAS  Google Scholar 

  10. Blythe JG, Wahl TP: Debulking surgery: Does it increase the quality of survival? Gynecol Oncol 1982, 14:396–408.

    Article  PubMed  CAS  Google Scholar 

  11. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6.

    Article  PubMed  CAS  Google Scholar 

  12. Burke TW, Morris M: Secondary cytoreductive surgery for ovarian cancer. Obstet Gynecol Clin North Am 1994, 21:167–178.

    PubMed  CAS  Google Scholar 

  13. Berek JS, Hacker NF, Lagasse LD, et al.: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983, 61:189–193.

    PubMed  CAS  Google Scholar 

  14. Morris M, Gershenson DM, Wharton T, et al.: Secondary cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1989, 34:334–338.

    Article  PubMed  CAS  Google Scholar 

  15. Jänicke F, Holscher M, Kuhn W, et al.: Radical surgical procedure improves survival time in patients with ovarian cancer. Cancer 1992, 70:2129–2136.

    Article  PubMed  Google Scholar 

  16. Segna RA, Dottino PR, Mabdeli JP, et al.: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993, 11:434–439.

    PubMed  CAS  Google Scholar 

  17. Eisenkop SM, Friedman RL, Wang HJ: Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer 1995, 76:1606–1614.

    Article  PubMed  CAS  Google Scholar 

  18. Vaccarello L, Rubin SC, Vlamis V, et al.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995, 57:61–65.

    Article  PubMed  CAS  Google Scholar 

  19. Landoni F, Pellegrino A, Cormio G, et al.: Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstet Gynecol Scand 1998, 77:233–237.

    Article  PubMed  CAS  Google Scholar 

  20. Cormio G, di Vagno G, Cazzolla A, et al.: Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Rep Biol 1999, 86:185–188.

    Article  CAS  Google Scholar 

  21. Gadducci A, Iacconi P, Cosio S, et al.: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000, 79:344–349.

    Article  PubMed  CAS  Google Scholar 

  22. Zang RY, Zhang ZY, Li ZT, et al.: Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 2000, 26:798–804.

    Article  PubMed  CAS  Google Scholar 

  23. Chen LM, Leuchter RS, Lagasse LD, Karlan BY: Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000, 77:362–368.

    Article  PubMed  CAS  Google Scholar 

  24. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000, 88:144–153. Comprehensive analysis highlighting the important prognostic determinants of the feasibility of secondary cytoreduction and the associated survival benefit.

    Article  PubMed  CAS  Google Scholar 

  25. Scarabelli C, Gallo A, Campagnutta E, Carbone A: Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma. Int J Gynaecol Cancer 1998, 8:215–221.

    Article  Google Scholar 

  26. Munkarah A, Levenback C, Wolf JK, et al.: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001, 81:237–241.

    Article  PubMed  CAS  Google Scholar 

  27. Tay EH, Grant PT, Gebski V, Hacker NF: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002, 99:1008–1013.

    Article  PubMed  Google Scholar 

  28. Meredith MA, Cliby WA, Keeney GL, et al.: Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 2003, 89:16–21.

    Article  Google Scholar 

  29. Zang RY, Li ZT, Tang J, et al.: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004, 100:1152–1161. A prospective analysis delineating patient selection criteria for secondary cytoreduction and demonstrating its survival benefit.

    Article  PubMed  Google Scholar 

  30. Güngör M, OrtaÇ F, Arvas M, et al.: The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 2005, 97:74–79.

    Article  PubMed  Google Scholar 

  31. Gronlund B, Lundvall L, Christensen IJ, et al.: Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 2005, 31:67–73.

    Article  PubMed  CAS  Google Scholar 

  32. Onda T, Yoshikawa H, Yamada M, et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 2005, 92:1026–1032. Retrospective study delineating criteria for the selection of candidates for secondary cytoreductive surgery in recurrent ovarian cancer.

    Article  PubMed  CAS  Google Scholar 

  33. Burke TW, Morris M: Secondary cytoreductive surgery operations. In Ovarian Cancer. Edited by Rubin SC, Sutton GP, New York: McGraw-Hill; 1993:301–312.

    Google Scholar 

  34. Chi DS, McCaughty K, Schwabenbauer S, et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian carcinoma [abstract 3]. Gynecol Oncol 2005, 96:910.

    Google Scholar 

  35. Lichtenegger W, Sehouli J, Buchmann E, et al.: Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 1998, 6:447–451.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, 21287, Baltimore, MD, USA

    Robert E. Bristow MD

Authors
  1. Teresa P. Díaz-Montes MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Bristow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Díaz-Montes, T.P., Bristow, R.E. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep 7, 451–458 (2005). https://doi.org/10.1007/s11912-005-0010-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0010-4

Keywords

Search

Navigation